Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abivax SA - American Depositary Shares (NQ:ABVX)

66.49 -3.27 (-4.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abivax SA - American Depositary Shares

< Previous 1 2 Next >
Intel, Absci, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
From Abivax
Via GlobeNewswire
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
From Abivax
Via GlobeNewswire
Abivax announces trading resumption of its ordinary shares on Euronext Paris
From Abivax
Via GlobeNewswire
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
From Abivax
Via GlobeNewswire
Abivax Announces Launch of Public Offering
From Abivax
Via GlobeNewswire
Crude Oil Falls; Thermo Fisher Scientific Earnings Top Views
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Dow Surges Over 200 Points; AT&T Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study
Abivax shares jump as obefazimod meets key Phase 3 trial endpoints in ulcerative colitis with strong remission rates and a favorable safety profile. 
Via Benzinga
Why Vicor Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket
Shares of Vicor Corporation (NASDAQ:VICR) rose sharply in pre-market trading after posting second-quarter results. 
Via Benzinga
Small-Cap Abivax Spikes 400% On Positive Late-Stage Ulcerative Colitis Drug Trial Results — Retail Buzz Builds Around Blockbuster Potential
The drug candidate demonstrated a placebo-adjusted remission rate of 19.3% in the first study and 13.4% in the second study. 
Via Stocktwits
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
From Abivax
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Friday?
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
Get insights into the top gainers and losers of Wednesday's pre-market session.
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Abivax Announces Results of its June 6, 2025 Annual General Meeting
From Abivax
Via GlobeNewswire
Abivax Presents First Quarter 2025 Financial Results
From Abivax
Via GlobeNewswire
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
From Abivax
Via GlobeNewswire
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
From Abivax
Via GlobeNewswire
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
From Abivax
Via GlobeNewswire
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
From Abivax
Via GlobeNewswire
Earnings Scheduled For March 24, 2025
 
Via Benzinga
Abivax Announces Full Year 2024 Financial Results
From Abivax
Via GlobeNewswire
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
From Abivax
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.